Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study to Treat High Phosphate Levels in the Blood.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Females and males aged ≥18 years~2. Chronic maintenance hemodialysis 3 x/week for a at least 3 months~3. Prescribed and taking at least 3 doses of phosphate binder per day~4. Serum phosphate levels should be between 3.5 and 8.0 mg/dL ; 1.13 mmol/L and 2.58 mmol/L (inclusive) at screening~5. Total serum calcium levels 2.0 - 2.6 mmol/L inclusive at screening~6. For randomization in the study, after up to 3 weeks wash out of phosphate binders, patients must have serum phosphate levels of at least 6. 0 mg/dL (1.94 mmol/L) but below 10 mg/dL (3.23 mmol/L) and have had an increase of at least 1.5 mg/dL (0.48 mmol/L) vs pre wash out~Exclusion Criteria:~1. Severe hyperphosphatemia defined as \>10 mg/dL on Phosphate-binders at all time points during clinical routine monitoring for the 3 preceding months before screening visit.~2. Serum parathyroid hormone \>1200 pg/mL~3. Significant metabolic acidosis~4. Clinical signs of hypovolemia at randomization~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 mg bid (Type: EXPERIMENTAL): 1 mg AZD1722 bid
- 3 mg bid (Type: EXPERIMENTAL): 3 mg AZD1722 bid
- 10 mg bid (Type: EXPERIMENTAL): 10 mg AZD1722 bid
- 30 mg bid (Type: EXPERIMENTAL): 30 mg AZD1722 bid
- 3 mg od (Type: EXPERIMENTAL): 3 mg AZD1722 od
- 30 mg od (Type: EXPERIMENTAL): 30 mg AZD1722 od
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (double dummy technique)

Based on this trial design, predict the completion outcome and termination type (if applicable).